**Supplementary material**

**Supplementary Table 1.** Estimated basic reproduction number (R0) from selected studies.

| Author | Publication date | Submission date | Publication delay | R0 | Uncertainty | Source |
| --- | --- | --- | --- | --- | --- | --- |
| Wu et al.(*1*) | 2020/1/23 | 2020/1/21 | 2.00 | 0.30 | 0.17-0.44 (95% CI) | Euro surveillance |
| Bedford et al.(*2*) | 2020/1/23 | 2020/1/23 | 0.00 | 2.50 | 1.50-3.50 | ResearchWorks |
| Riou et al.(*3*) | 2020/1/24 | 2020/1/23 | 1.00 | 2.20 | 1.40-3.80 (90% CI) | BioRxiv |
| Zhao et al.(*4*) | 2020/1/24 | 2020/1/23 | 1.00 | 2.24 | 1.96-2.55 (95% CI) | bioRxiv |
| Zhao et al.(*4*) | 2020/1/24 | 2020/1/23 | 1.00 | 3.58 | 2.89-4.39 (95% CI) | bioRxiv |
| Natsuko et al.(*5*) | 2020/1/25 | 2020/1/25 | 0.00 | 2.60 | 1.50-3.50 (best-worst scenario) | Imperial College London |
| Shen et al.(*6*) | 2020/1/25 | 2020/1/24 | 1.00 | 4.71 | 4.5-4.92 | bioRxiv |
| Liu et al.(*7*) | 2020/1/26 | 2020/1/25 | 1.00 | 2.90 | 2.32-3.63 (95% CI) | bioRxiv |
| Liu et al.(*7*) | 2020/1/26 | 2020/1/25 | 1.00 | 2.92 | 2.28-3.67 (95% CI) | bioRxiv |
| Read et al.(*8*) | 2020/1/28 | 2020/1/27 | 1.00 | 3.11 | 2.39-4.13 (95% CI) | medRxiv |
| Li et al.(*9*) | 2020/1/29 | 2020/1/22 | 7.00 | 2.20 | 1.40-3.90 (95% CI) | NEJM |
| Cao et al.(*10*) | 2020/1/29 | 2020/1/27 | 2.00 | 4.08 | 3.37-4.77 (95% CI) | medRxiv |
| Wu et al.(*11*) | 2020/1/31 | 2020/1/28 | 3.00 | 2.68 | 2.48-2.86 (95% CI) | The Lancet |
| Zhao et al.(*12*) | 2020/2/1 | 2020/1/27 | 5.00 | 2.56 | 2.49-2.63 (95% CI) | J Clin Med |
| Chen(*13*) | 2020/2/4 | 2020/1/28 | 7.00 | 3.50 | 1.5-5.5 | Microbes Infect |
| Tang et al.(*14*) | 2020/2/7 | 2020/1/31 | 7.00 | 6.47 | 5.71-7.23 (95% CI) | J Clin Med |
| Zhao et al.(*15*) | 2020/2/9 | 2020/2/6 | 3.00 | 5.70 | 3.40-9.20 (95% CI) | medRxiv |
| Cao et al.(*16*) | 2020/2/9 | 2020/2/7 | 2.00 | 3.24 | .. | medRxiv |
| Hermanowicz(*17*) | 2020/2/10 | 2020/2/8 | 2.00 | 2.45 | 2.40-2.50 | medRxiv |
| Chinazzi et al.(*18*) | 2020/2/11 | 2020/2/9 | 2.00 | 2.40 | 2.20-2.60 (90% CI) | medRxiv |
| Xiong et al.(*19*) | 2020/2/12 | 2020/2/10 | 2.00 | 2.70 | .. | medRxiv |
| Liu et al.(*20*) | 2020/2/13 | 2020/2/13 | 0.00 | 4.50 | 4.40-4.60 (95% CI) | bioRxiv |
| Liu et al.(*20*) | 2020/2/13 | 2020/2/13 | 0.00 | 4.40 | 4.30-4.60 (95% CI) | bioRxiv |
| Jung et al.(*21*) | 2020/2/14 | 2020/1/29 | 16.00 | 2.10 | 2.00-2.20 | J Clin Med |
| Jung et al.(*21*) | 2020/2/14 | 2020/1/29 | 16.00 | 3.20 | 2.70-3.70 | J Clin Med |
| Zhang et al.(*22*) | 2020/2/18 | 2020/2/16 | 2.00 | 3.60 | .. | medRxiv |
| Zhang et al.(*23*) | 2020/2/18 | 2020/2/16 | 2.00 | 1.44 | 1.40-1.47 (IQRs) | medRxiv |
| Zhou(*24*) | 2020/2/20 | 2020/2/20 | 0.00 | 2.12 | 2.04-2.18 | medRxiv |
| Shao et al.(*25*) | 2020/2/20 | 2020/2/20 | 0.00 | 3.30 | 3.25-3.40 | medRxiv |
| Liu et al.(*26*) | 2020/2/22 | 2020/2/22 | 0.00 | 3.56 | 2.31-4.81 (95% CI) | medRxiv |
| Lai et al.(*27*) | 2020/2/23 | 2020/2/19 | 4.00 | 2.60 | 2.10-5.10 (95% CI) | medRxiv |
| Zhang et al.(*28*) | 2020/2/25 | 2020/2/24 | 1.00 | 5.60 | .. | medRxiv |
| Park et al.(*29*) | 2020/2/28 | 2020/2/28 | 0.00 | 2.90 | 2.10-4.50 (95% CI) | medRxiv |
| Hao(*30*) | 2020/3/2 | 2020/3/2 | 0.00 | 1.50 | .. | medRxiv |
| Hao(*30*) | 2020/3/2 | 2020/3/2 | 0.00 | 3.50 | .. | medRxiv |
| Tang et al.(*31*) | 2020/3/3 | 2020/3/3 | 0.00 | 2.90 | 2.74-3.06 | medRxiv |
| Tang et al.(*32*) | 2020/3/6 | 2020/2/18 | 17.00 | 3.27 | 2.98-3.58 (95% CI) | International Journal of Infectious Diseases |
| Ganyani et al.(*33*) | 2020/3/8 | 2020/3/5 | 3.00 | 1.59 | 1.42-1.78 (95% CI) | medRxiv |
| Wang et al.(*34*) | 2020/3/10 | 2020/3/8 | 2.00 | 2.82 | 2.71-2.93 (95% CI) | medRxiv |
| Wan et al.(*35*) | 2020/3/10 | 2020/3/10 | 0.00 | 3.36 | 3.20-3.64 (95% CI) | medRxiv |
| Yang et al.(*36*) | 2020/3/11 | 2020/2/15 | 25.00 | 4.25 | .. | Mathematical Biosciences and Engineering |
| A. Cleo G et al.(*37*) | 2020/3/12 | 2020/3/12 | 0.00 | 2.60 | .. | medRxiv |
| Mizumoto et al.(*38*) | 2020/3/13 | 2020/3/13 | 0.00 | 5.20 | 5.04-5.47 (95% CI) | medRxiv |
| Tang et al.(*39*) | 2020/3/13 | 2020/3/9 | 4.00 | 3.80 | 3.50-4.20 (95% CI) | medRxiv |
| Tang et al.(*39*) | 2020/3/13 | 2020/3/9 | 4.00 | 3.00 | 2.60-3.30 (95% CI) | medRxiv |
| Wang et al.(*40*) | 2020/3/16 | 2020/3/10 | 6.00 | 4.00 | .. | medRxiv |
| Jia et al.(*41*) | 2020/3/20 | 2020/3/18 | 2.00 | 3.15 | 1.71-5.21 (95% CI) | medRxiv |

**Supplementary Table 2.** Estimated infectious period from selected studies.

| Author` | Publication date | Submission date | Publication delay | Infectious period | Uncertainty | Source |
| --- | --- | --- | --- | --- | --- | --- |
| Read et al.(*8*) (v1) | 2020/1/24 | 2020/1/23 | 1.00 | 3.60 | .. | medRxiv |
| Nishiura et al.(*42*) | 2020/1/24 | 2020/1/22 | 2.00 | 9.30 | .. | J Clin Med |
| Read et al.(*8*) (v2) | 2020/1/28 | 2020/1/27 | 1.00 | 1.61 | 0.35-3.23 (95% CI) | medRxiv |
| Li et al.(*9*) | 2020/1/29 | 2020/1/22 | 7.00 | 7.50 | .. | NEJM |
| Cao et al.(*10*) | 2020/1/29 | 2020/1/27 | 2.00 | 9.00 | .. | medRxiv |
| Wu et al.(*11*) | 2020/1/31 | 2020/1/28 | 3.00 | 1.40 | .. | The Lancet |
| Wang et al.(*43*) | 2020/2/4 | 2020/1/29 | 6.00 | 14.00 | .. | SSRN |
| Nishiura et al.(*44*) | 2020/2/4 | 2020/2/2 | 2.00 | 3.60 | .. | J Clin Med |
| Chowell et al.(*45*) | 2020/2/5 | 2020/2/3 | 2.00 | 7.00 | .. | medRxiv |
| Cao et al.(*16*) | 2020/2/9 | 2020/2/7 | 2.00 | 9.00 | .. | medRxiv |
| Xiong et al.(*19*) | 2020/2/12 | 2020/2/10 | 2.00 | 13.00 | .. | medrxiv |
| Zhu et al.(*46*) | 2020/2/16 | 2020/2/15 | 1.00 | 14.30 | .. | medrxiv |
| Li et al.(*47*) | 2020/2/17 | 2020/2/14 | 3.00 | 3.45 | 2.91-3.84 (95% CI) | medrxiv |
| You et al.(*48*) | 2020/2/17 | 2020/2/15 | 2.00 | 10.91 | 6.96-14.86 | medRxiv |
| Keeling et al.(*49*) | 2020/2/17 | 2020/2/14 | 3.00 | 1.61 | .. | medRxiv |
| Zhang et al.(*23*) | 2020/2/18 | 2020/2/16 | 2.00 | 7.50 | 1.00-14.00 | medrxiv |
| Zhou(*24*) | 2020/2/20 | 2020/2/19 | 1.00 | 5.40 | .. | medRxiv |
| Maier et al.(*50*) | 2020/2/20 | 2020/2/18 | 2.00 | 8.00 | .. | medRxiv |
| Zhang et al.(*51*) | 2020/2/23 | 2020/2/21 | 2.00 | 5.10 | .. | medRxiv |
| Lai et al.(*27*) | 2020/2/23 | 2020/2/19 | 4.00 | 7.5 | 5.30-19.00 | medRxiv |
| Lin et al.(*52*) | 2020/2/25 | 2020/2/21 | 4.00 | 7.50 | 6.00-9.00 | medrxiv |
| Zhang et al.(*28*) | 2020/2/25 | 2020/2/24 | 1.00 | 5.00 | .. | medRxiv |
| Boldog et al.(*53*) | 2020/2/27 | 2020/2/26 | 1.00 | 3.30 | 1.70-5.60 | medrxiv |
| Chen et al.(*54*) | 2020/2/28 | 2020/1/28 | 31.00 | 5.80 | .. | Infect Dis Poverty |
| Neher et al.(*55*) | 2020/3/3 | 2020/3/2 | 1.00 | 5.00 | .. | medRxiv |
| Lin et al.(*56*) | 2020/3/4 | 2020/1/31 | 33.00 | 4.00 | .. | Int J Infect Dis |
| Kissler et al.(*57*) | 2020/3/6 | 2020/3/4 | 2.00 | 4.90 | .. | medRxiv |
| Zhang et al.(*58*) | 2020/3/6 | 2020/3/4 | 2.00 | 2.26 | 2.14-2.39 (95% CI) | medRxiv |
| Zhang et al.(*58*) | 2020/3/6 | 2020/3/4 | 2.00 | 3.75 | 3.43-4.13 (95% CI) | medRxiv |
| Zhao et al.(*59*) | 2020/3/8 | 2020/3/5 | 3.00 | 6.00 | .. | medRxiv |
| Wang et al.(*34*) | 2020/3/10 | 2020/3/8 | 2.00 | 4.11 | 3.56-4.65 | medRxiv |

**Supplementary Table 3.** Estimated incubation period from selected studies.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Author | Publication date | Submission date | Publication delay | Incubation period | Uncertainty | Source |
| Wang et al.(*60*) | 2020/1/24 | 2020/1/23 | 1.00 | 5.00 | 3.00-7.00 | The Lancet |
| Chan et al.(*61*) | 2020/1/24 | 2020/1/22 | 2.00 | 4.50 | 3.00-6.00 | The Lancet |
| Nishiura et al.(*42*) | 2020/1/24 | 2020/1/22 | 2.00 | 3.20 | .. | J Clin Med |
| Zhao et al.(*4*) | 2020/1/24 | 2020/1/23 | 1.00 | 5.00 | .. | bioRxiv |
| Mike(*62*) | 2020/1/26 | 2020/1/26 | 0.00 | 5.40 | 4.20-6.70 (95% CI) | NA |
| Liu et al.(*20*) | 2020/1/26 | 2020/1/25 | 1.00 | 4.80 | 2.00-11.00 | bioRxiv |
| WHO(*63*) | 2020/1/27 | 2020/1/27 | 0.00 | 5.20 | .. | WHO |
| Read et al.(*8*) | 2020/1/28 | 2020/1/27 | 1.00 | 3.00 | 0.00-6.00 | medRxiv |
| Shao et al.(*64*) | 2020/1/28 | 2020/1/28 | 0.00 | 7.00 | .. | bioRxiv |
| Backer et al.(*65*) | 2020/1/28 | 2020/1/27 | 1.00 | 5.80 | .. | medRxiv |
| Li et al.(*9*) | 2020/1/29 | 2020/1/23 | 6.00 | 5.20 | 4.10-7.00 (95% CI) | NEJM |
| Wu et al.(*11*) | 2020/1/31 | 2020/1/29 | 2.00 | 6.00 | .. | The Lancet |
| Lauer et al.(*66*) | 2020/2/4 | 2020/2/2 | 2.00 | 5.20 | 4.40-6.00 (95% CI) | medRxiv |
| Lauer et al.(*66*) | 2020/2/4 | 2020/2/2 | 2.00 | 5.10 | .. | medRxiv |
| Ai et al.(*67*) | 2020/2/5 | 2020/2/4 | 1.00 | 5.00 | 3.00-7.00 | medRxiv |
| Chowell et al.(*45*) | 2020/2/5 | 2020/2/3 | 2.00 | 5.00 | .. | medRxiv |
| Backer et al.(*68*) | 2020/2/6 | 2020/1/27 | 10.00 | 6.40 | 5.60-7.70 (95% CI) | EuroSurveill |
| Li(*69*) | 2020/2/7 | 2020/2/6 | 1.00 | 7.00 | 7.80-9.00 | arXiv |
| Tang et al.(*14*) | 2020/2/7 | 2020/1/31 | 7.00 | 7.00 | .. | J Clin Med |
| Guan et al.(*70*) | 2020/2/9 | 2020/2/6 | 3.00 | 3.00 | 0.00-24.00 | medRxiv |
| Sanche et al.(*71*) | 2020/2/11 | 2020/2/7 | 4.00 | 4.20 | 3.50-5.10 (95% CI) | medRxiv |
| Linton et al.(*72*) | 2020/2/17 | 2020/1/25 | 23.00 | 5.00 | 2.00-14.00 | J Clin Med |
| Du et al.(*73*) | 2020/2/17 | 2020/2/16 | 1.00 | 5.50 | 5.00-6.00 | medRxiv |
| Leung(*74*) | 2020/2/18 | 2020/2/13 | 5.00 | 1.80 | 1.00-2.70 | medRxiv |
| Leung(*74*) | 2020/2/18 | 2020/2/13 | 5.00 | 6.90 | 5.50-8.30 | medRxiv |
| WHO(*75*) | 2020/2/19 | 2020/2/19 | 0.00 | 5.50 | .. | WHO |
| Sun et al.(*76*) | 2020/2/20 | 2020/2/18 | 2.00 | 4.50 | 3.00–5.50 (IQRs) | The Lancet Digital Health |
| Ding et al.(*77*) | 2020/2/20 | 2020/2/18 | 2.00 | 3.00 | 1.00-6.00 | medRxiv |
| Yang et al.(*78*) | 2020/2/21 | 2020/2/20 | 1.00 | 5.00 | .. | medRxiv |
| Zhang et al.(*51*) | 2020/2/23 | 2020/2/21 | 2.00 | 5.20 | 1.80-12.40 | medRxiv |
| Wang et al.(*79*) | 2020/2/25 | 2020/2/22 | 3.00 | 8.50 | 3.00-14.00 | medRxiv |
| Chong(*80*) | 2020/2/25 | 2020/2/22 | 3.00 | 10.91 | .. | medRxiv |
| Guan et al.(*81*) | 2020/2/27 | 2020/2/25 | 2.00 | 3.60 | .. | medRxiv |
| Yang et al.(*82*) | 2020/2/28 | 2020/2/27 | 1.00 | 7.00 | 2.00-14.00 | Journal of Thoracic Disease |
| Guan et al.(*83*) | 2020/2/28 | 2020/2/6 | 22.00 | 4.00 | 2.00-7.00 (IQRs) | NEJM |
| Li et al.(*84*) | 2020/2/29 | 2020/2/27 | 2.00 | 7.00 | .. | medRxiv |
| Han(*85*) | 2020/2/29 | 2020/2/24 | 5.00 | 5.84 | .. | medRxiv |
| Yang et al.(*86*) | 2020/3/3 | 2020/2/28 | 4.00 | 3.70 | 3.00-7.00 | medRxiv |
| Bi et al.(*87*) | 2020/3/4 | 2020/3/3 | 1.00 | 4.80 | 4.20-5.40 (95% CI) | medRxiv |
| Tindale et al.(*88*) | 2020/3/6 | 2020/3/3 | 3.00 | 9.00 | 7.92-10.20 (95% CI) | medRxiv |
| Kissler et al.(*57*) | 2020/3/6 | 2020/3/4 | 2.00 | 5.00 | 3.40-6.00 | medRxiv |
| Ping(*89*) | 2020/3/6 | 2020/3/1 | 5.00 | 8.06 | 6.89-9.36 (95% CI) | medRxiv |
| Kraemer et al(*90*) | 2020/3/6 | 2020/3/2 | 4.00 | 5.10 | .. | medRxiv |
| Su et al.(*91*) | 2020/3/8 | 2020/3/6 | 2.00 | 5.50 | 0.00-14.00 | medRxiv |
| Ganyani et al.(*33*) | 2020/3/8 | 2020/3/5 | 3.00 | 5.20 | .. | medRxiv |
| Jing et al.(*92*) | 2020/3/10 | 2020/3/6 | 4.00 | 8.13 | 7.37-8.91 (95% CI) | medRxiv |
| Jing et al.(*92*) | 2020/3/10 | 2020/3/6 | 4.00 | 8.62 | 8.02-9.28 (95% CI) | medRxiv |
| Yang et al.(*36*) | 2020/3/11 | 2020/2/15 | 25.00 | 7.00 | .. | Mathematical Biosciences and Engineering |
| Li et al.(*47*) | 2020/3/16 | 2020/2/15 | 30.00 | 3.69 | 3.28-4.03 (95% CI) | Science |
| Li et al.(*47*) | 2020/3/16 | 2020/2/15 | 30.00 | 3.6 | 3.41-3.91 (95% CI) | Science |
| Li et al.(*47*) | 2020/3/16 | 2020/2/15 | 30.00 | 3.44 | 3.26-4.06 (95% CI) | Science |
| Bi et al.(*87*) | 2020/3/19 | 2020/3/18 | 1.00 | 4.80 | 4.20-5.40 (95% CI) | medRxiv |

**Supplementary Table 4.** Estimated case-fatality-rate (CFR) from selected studies.

| Author | Publication date | Submission date | Publication delay | CFR | Uncertainty | Source |
| --- | --- | --- | --- | --- | --- | --- |
| Shen et al.(*6*) | 2020/1/25 | 2020/1/24 | 1.00 | 11.02% | 9.26%-12.78% (95% CI) | medRxiv |
| Liu et al.(*7*) | 2020/1/26 | 2020/1/25 | 1.00 | 3.00% | .. | BioRxiv |
| Cao et al.(*10*) | 2020/1/29 | 2020/1/27 | 2.00 | 6.50% | .. | medRxiv |
| Chen(*13*) | 2020/2/4 | 2020/1/28 | 7.00 | 3.00% | .. | Microbes Infect |
| Cao et al.(*16*) | 2020/2/9 | 2020/2/7 | 2.00 | 1.50% | .. | medRxiv |
| Guan et al.(*70*) | 2020/2/9 | 2020/2/6 | 3.00 | 1.40% | .. | medRxiv |
| Dorigatti et al.(*93*) | 2020/2/10 | 2020/2/10 | 0.00 | 18.00% | 11.00%-81.00% (95% CI) | NA |
| Dorigatti et al.(*93*) | 2020/2/10 | 2020/2/10 | 0.00 | 3.40% | 1.20%-5.60% | NA |
| Liu et al.(*20*) | 2020/2/13 | 2020/2/12 | 1.00 | 2.80% | .. | bioRxiv |
| Liu et al.(*20*) | 2020/2/13 | 2020/2/12 | 1.00 | 0.24% | .. | bioRxiv |
| Shen et al.(*94*) | 2020/2/13 | 2020/2/11 | 2.00 | 3.44% | 3.19%-3.70% | medRxiv |
| Jung et al.(*21*) | 2020/2/14 | 2020/1/29 | 16.00 | 5.30% | 3.50%-7.60% (95% CI) | J Clin Med |
| Jung et al.(*21*) | 2020/2/14 | 2020/1/29 | 16.00 | 8.40% | 5.30%-12.30% (95% CI) | J Clin Med |
| Guan et al.(*70*) | 2020/2/17 | 2020/2/14 | 3.00 | 8.90% | 6.20%-12.60% (95% CI) | medRxiv |
| Zhang et al.(*95*) | 2020/2/17 | 2020/2/16 | 1.00 | 4.08% | 1.52%-6.64% | medRxiv |
| Zhang et al.(*95*) | 2020/2/17 | 2020/2/16 | 1.00 | 1.32% | 0.00%-2.64% | medRxiv |
| Wilson et al.(*96*) | 2020/2/18 | 2020/2/15 | 3.00 | 1.37% | 0.57%-3.22% (95% CI) | medRxiv |
| Sun et al.(*76*) | 2020/2/20 | 2020/2/1 | 19.00 | 8.00% | .. | The Lancet Digital Health |
| Diao et al.(*97*) | 2020/2/20 | 2020/2/18 | 2.00 | 7.00% | .. | medRxiv |
| Mizumoto et al.(*98*) | 2020/2/23 | 2020/2/19 | 4.00 | 18.90% | 17.10%-20.80% (95% CI) | medRxiv |
| Mizumoto et al.(*98*) | 2020/2/23 | 2020/2/19 | 4.00 | 6.10% | 5.20%-7.10% (95% CI) | medRxiv |
| Mizumoto et al.(*98*) | 2020/2/23 | 2020/2/19 | 4.00 | 0.90% | 0.60%-1.30% (95% CI) | medRxiv |
| Sun et al.(*99*) | 2020/2/25 | 2020/2/24 | 1.00 | 4.30% | .. | medRxiv |
| Ying et al.(*100*) | 2020/2/27 | 2020/2/24 | 3.00 | 2.84% | .. | medRxiv |
| Ying et al.(*100*) | 2020/2/27 | 2020/2/24 | 3.00 | 3.27% | .. | medRxiv |
| Ying et al.(*100*) | 2020/2/27 | 2020/2/24 | 3.00 | 0.73% | .. | medRxiv |
| Qi et al.(*101*) | 2020/3/3 | 2020/3/2 | 1.00 | 5.40% | .. | medRxiv |
| Qi et al.(*101*) | 2020/3/3 | 2020/3/2 | 1.00 | 0.85% | 0.80%-0.90% | medRxiv |
| Riou et al.(*102*) | 2020/3/6 | 2020/3/4 | 2.00 | 1.60% | 1.40%-1.80% | medRxiv |
| Li et al.(*103*) | 2020/3/6 | 2020/3/5 | 1.00 | 2.38% | .. | medRxiv |
| Deng et al.(*104)* | 2020/3/6 | 2020/3/4 | 2.00 | 1.07% | 0.89%-1.24% | medRxiv |
| Tindale et al.(*88*) | 2020/3/6 | 2020/3/3 | 3.00 | 2.20% | .. | medRxiv |
| Russell W et al.(*105*) | 2020/3/9 | 2020/3/8 | 1.00 | 2.30% | 0.75%-5.30% | medRxiv |
| Russell W et al.(*105*) | 2020/3/9 | 2020/3/8 | 1.00 | 1.10% | 0.30%-2.40% | medRxiv |
| Baud et al.(*106*) | 2020/3/12 | 2020/3/1 | 11.00 | 5.60% | 5.40%-5.80% | The Lancet Infectious Diseases |
| Mizumoto et al.(*38*) | 2020/3/13 | 2020/3/12 | 1.00 | 4.19% | .. | medRxiv |

**Supplementary References**

1. Wu P, Hao X, Lau EHY, Wong JY, Leung K, Wu JT, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Eurosurveillance. 2020;25(3):2000044.
2. Bedford T, Neher R, Hadfield J, Hodcroft E, Ilcisin M, Muller N. Genomic analysis of nCoV spread. Situation report 2020-01-23. ResearchWorks Archive. 2020 2020-01-23.
3. Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019-nCoV. bioRxiv. 2020.
4. Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. bioRxiv. 2020.
5. Imai N, Cori A, Dorigatti I, Baguelin M, Donnelly CA, Riley S, et al. Report 3 - Transmissibility of 2019-nCoV. 2020.
6. Shen M, Peng Z, Xiao Y, Zhang L. Modelling the epidemic trend of the 2019 novel coronavirus outbreak in China. bioRxiv. 2020.
7. Liu T, Hu J, Kang M, Lin L, Zhong H, Xiao J, et al. Transmission Dynamics of 2019 Novel Coronavirus (2019-nCoV). bioRxiv. 2020.
8. Read JM, Bridgen JR, Cummings DA, Ho A, Jewell CP. Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions. medRxiv. 2020:2020.01.23.20018549.
9. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. The New England Journal of Medicine. 2020.
10. Cao Z, Zhang Q, Lu X, Pfeiffer D, Jia Z, Song H, et al. Estimating the effective reproduction number of the 2019-nCoV in China. medRxiv. 2020:2020.01.27.20018952.
11. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. The Lancet. 2020;395(10225):689-97.
12. Zhao S, Musa SS, Lin Q, Ran J, Yang G, Wang W, et al. Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early Outbreak. Journal of Clinical Medicine. 2020;9(2):388.
13. Chen J. Pathogenicity and Transmissibility of 2019-nCoV—A Quick Overview and Comparison with Other Emerging Viruses. Microbes and Infection. 2020;22(2):69-71.
14. Tang B, Wang X, Li Q, Bragazzi NL, Tang S, Xiao Y, et al. Estimation of the Transmission Risk of the 2019-nCoV and Its Implication for Public Health Interventions. Journal of Clinical Medicine. 2020;9(2):462.
15. Zhao Q, Chen Y, Small DS. Analysis of the epidemic growth of the early 2019-nCoV outbreak using internationally confirmed cases. medRxiv. 2020.
16. Cao Z, Zhang Q, Lu X, Pfeiffer D, Wang L, Song H, et al. Incorporating Human Movement Data to Improve Epidemiological Estimates for 2019-nCoV. medRxiv. 2020:2020.02.07.20021071.
17. Hermanowicz SW. Forecasting the Wuhan coronavirus (2019-nCoV) epidemics using a simple (simplistic) model - update (Feb. 8, 2020). medRxiv. 2020.
18. Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S, et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (2019-nCoV) outbreak. medRxiv. 2020.
19. Xiong H, Yan H. Simulating the infected population and spread trend of 2019-nCov under different policy by EIR model. medRxiv. 2020.
20. Liu T, Hu J, Xiao J, He G, Kang M, Rong Z, et al. Time-varying transmission dynamics of Novel Coronavirus Pneumonia in China. bioRxiv. 2020:2020.01.25.919787.
21. Jung S-m, Akhmetzhanov AR, Hayashi K, Linton NM, Yang Y, Yuan B, et al. Real-Time Estimation of the Risk of Death from Novel Coronavirus (COVID-19) Infection: Inference Using Exported Cases. Journal of Clinical Medicine. 2020;9(2):523.
22. Zhang B, Zhou H, Zhou F. Study on SARS-COV-2 transmission and the effects of control measures in China. medRxiv. 2020.
23. Zhang L, Wan K, Chen J, Lu C, Dong L, Wu Z. When will the battle against novel coronavirus end in Wuhan: a SEIR modeling analysis. medRxiv. 2020.
24. Zhou C. Evaluating new evidence in the early dynamics of the novel coronavirus COVID-19 outbreak in Wuhan, China with real time domestic traffic and potential asymptomatic transmissions. medRxiv. 2020.
25. Shao N, Cheng J, Chen W. The reproductive number R0 of COVID-19 based on estimate of a statistical time delay dynamical system. medRxiv. 2020.
26. Liu Q, Liu Z, Li D, Gao Z, Zhu J, Yang J, et al. Assessing the Tendency of 2019-nCoV (COVID-19) Outbreak in China. medRxiv. 2020:2020.02.09.20021444.
27. Lai A, Bergna A, Acciarri C, Galli M, Zehender G. Early Phylogenetic Estimate Of The Effective Reproduction Number Of 2019-nCoV. medRxiv. 2020.
28. Zhang KK, Xie L, Lawless L, Zhou H, Gao G, Xue C. Characterizing the transmission and identifying the control strategy for COVID-19 through epidemiological modeling. medRxiv. 2020.
29. Park SW, Bolker BM, Champredon D, Earn DJD, Li M, Weitz JS, et al. Reconciling early-outbreak estimates of the basic reproductive number and its uncertainty: framework and applications to the novel coronavirus (SARS-CoV-2) outbreak. medRxiv. 2020:2020.01.30.20019877.
30. Hao T. Infection Dynamics of Coronavirus Disease 2019 (Covid-19) Modeled with the Integration of the Eyring Rate Process Theory and Free Volume Concept. medRxiv. 2020:2020.02.26.20028571.
31. Tang K, Huang Y, Chen M. Novel Coronavirus 2019 (Covid-19) epidemic scale estimation: topological network-based infection dynamic model. medRxiv. 2020:2020.02.20.20023572.
32. Tang B, Xia F, Tang S, Bragazzi NL, Li Q, Sun X, et al. The effectiveness of quarantine and isolation determine the trend of the COVID-19 epidemics in the final phase of the current outbreak in China. International Journal of Infectious Diseases. 2020.
33. Ganyani T, Kremer C, Chen D, Torneri A, Faes C, Wallinga J, et al. Estimating the generation interval for COVID-19 based on symptom onset data. medRxiv. 2020:2020.03.05.20031815.
34. Wang M, Qi J. A deterministic epidemic model for the emergence of COVID-19 in China. medRxiv. 2020:2020.03.08.20032854.
35. Wan H, Cui J-a, Yang G-J. Risk estimation and prediction by modeling the transmission of the novel coronavirus (COVID-19) in mainland China excluding Hubei province. medRxiv. 2020:2020.03.01.20029629.
36. Yang C, Wang J. A mathematical model for the novel coronavirus epidemic in Wuhan, China. Mathematical Biosciences and Engineering. 2020;17(3):2708-24.
37. Anastassopoulou CG, Russo L, Tsakris A, Siettos C. Data-Based Analysis, Modelling and Forecasting of the COVID-19 outbreak. medRxiv. 2020.
38. Mizumoto K, Kagaya K, Chowell G. Early epidemiological assessment of the transmission potential and virulence of coronavirus disease 2019 (COVID-19) in Wuhan City: China, January-February, 2020. medRxiv. 2020:2020.02.12.20022434.
39. Tang B, Xia F, Bragazzi NL, Wang X, He S, Sun X, et al. Lessons drawn from China and South Korea for managing COVID-19 epidemic: insights from a comparative modeling study. medRxiv. 2020:2020.03.09.20033464.
40. Wang Y, Teunis PFM. Strongly heterogeneous transmission of COVID-19 in mainland China: local and regional variation. medRxiv. 2020:2020.03.10.20033852.
41. Jia W, Han K, Song Y, Cao W, Wang S, Yang S, et al. Extended SIR prediction of the epidemics trend of COVID-19 in Italy and compared with Hunan, China. medRxiv. 2020:2020.03.18.20038570.
42. Nishiura H, Jung S, Linton NM, Kinoshita R, Yang Y, Hayashi K, et al. The Extent of Transmission of Novel Coronavirus in Wuhan, China, 2020. Journal of Clinical Medicine. 2020;9(2):330.
43. Wang H, Wang Z, Dong Y, Chang R, Xu C, Yu X, et al. Estimating the Number of 2019 Novel Coronavirus Cases in Chinese Mainland. SSRN. 2020.
44. Nishiura H, Kobayashi T, Yang Y, Hayashi K, Miyama T, Kinoshita R, et al. The Rate of Underascertainment of Novel Coronavirus (2019-nCoV) Infection: Estimation Using Japanese Passengers Data on Evacuation Flights. Journal of Clinical Medicine. 2020;9(2):419.
45. Chowell G, Dhillon R, Srikrishna D. Getting to zero quickly in the 2019-nCov epidemic with vaccines or rapid testing. medRxiv. 2020:2020.02.03.20020271.
46. Zhu X, Zhang A, Xu S, Jia P, Tan X, Tian J, et al. Spatially Explicit Modeling of 2019-nCoV Epidemic Trend based on Mobile Phone Data in Mainland China. medRxiv. 2020:2020.02.09.20021360.
47. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (COVID-19). medRxiv. 2020:2020.02.14.20023127.
48. You C, Deng Y, Hu W, Sun J, Lin Q, Zhou F, et al. Estimation of the Time-Varying Reproduction Number of COVID-19 Outbreak in China. medRxiv. 2020:2020.02.08.20021253.
49. Keeling MJ, Hollingsworth TD, Read JM. The Efficacy of Contact Tracing for the Containment of the 2019 Novel Coronavirus (COVID-19). medRxiv. 2020:2020.02.14.20023036.
50. Maier BF, Brockmann D. Effective containment explains sub-exponential growth in confirmed cases of recent COVID-19 outbreak in Mainland China. medRxiv. 2020:2020.02.18.20024414.
51. Zhang J, Litvinova M, Wang W, Wang Y, Deng X, Chen X, et al. Evolving epidemiology of novel coronavirus diseases 2019 and possible interruption of local transmission outside Hubei Province in China: a descriptive and modeling study. medRxiv. 2020:2020.02.21.20026328.
52. Lin H, Liu W, Gao H, Nie J, Fan Q. Trends in Transmissibility of 2019 Novel Coronavirus-Infected Pneumonia in Wuhan and 29 Provinces in China. medRxiv. 2020.
53. Boldog P, Tekeli T, Vizi Z, Denes A, Bartha F, Rost G. Risk assessment of novel coronavirus COVID-19 outbreaks outside China. medRxiv. 2020:2020.02.04.20020503.
54. Chen T, Rui J, Wang Q, Zhao Z, Cui J, Yin L. A mathematical model for simulating the phase-based transmissibility of a novel coronavirus. Infectious Diseases of Poverty. 2020;9(1):24.
55. Neher RA, Dyrdak R, Druelle V, Hodcroft EB, Albert J. Potential impact of seasonal forcing on a SARS-CoV-2 pandemic. medRxiv. 2020:2020.02.13.20022806.
56. Lin Q, Zhao S, Gao D, Lou Y, Yang S, Musa SS, et al. A conceptual model for the coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China with individual reaction and governmental action. International Journal of Infectious Diseases. 2020;93:211-6.
57. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the post-pandemic period. medRxiv. 2020:2020.03.04.20031112.
58. Zhang Y, Jiang B, Yuan J, Tao Y. The impact of social distancing and epicenter lockdown on the COVID-19 epidemic in mainland China: A data-driven SEIQR model study. medRxiv. 2020:2020.03.04.20031187.
59. Zhao Z, Zhu Y-Z, Xu J-W, Hu Q-Q, Lei Z, Rui J, et al. A mathematical model for estimating the age-specific transmissibility of a novel coronavirus. medRxiv. 2020:2020.03.05.20031849.
60. Wang C, Horby P, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. The Lancet. 2020;395(10223):470-3.
61. Chan JFW, Yuan S, Kok K, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet. 2020;395(10223):514-23.
62. Mike F. nCoV: incubation period distribution. 2020.
63. Novel Coronavirus (2019-nCoV) Situation Report-7 WHO. 2020.
64. Shao P, Shan Y. Beware of asymptomatic transmission: Study on 2019-nCoV prevention and control measures based on extended SEIR model. bioRxiv. 2020:2020.01.28.923169.
65. Backer JA, Klinkenberg D, Wallinga J. The incubation period of 2019-nCoV infections among travellers from Wuhan, China. medRxiv. 2020:2020.01.27.20018986.
66. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith H, et al. The incubation period of 2019-nCoV from publicly reported confirmed cases: estimation and application. medRxiv. 2020:2020.02.02.20020016.
67. Ai S, Zhu G, Tian F, Li H, Gao Y, Wu Y, et al. Population movement, city closure and spatial transmission of the 2019-nCoV infection in China. medRxiv. 2020:2020.02.04.20020339.
68. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020. Eurosurveillance. 2020;25(5):2000062.
69. Li J. A Robust Stochastic Method of Estimating the Transmission Potential of 2019-nCoV. arXiv: Populations and Evolution. 2020.
70. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 2020:2020.02.06.20020974.
71. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. The Novel Coronavirus, 2019-nCoV, is Highly Contagious and More Infectious Than Initially Estimated. medRxiv. 2020:2020.02.07.20021154.
72. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung S, et al. Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. Journal of Clinical Medicine. 2020;9(2):538.
73. Du Z, Wang L, Cauchemez S, Xu X, Wang X, Cowling BJ, et al. Risk for Transportation of 2019 Novel Coronavirus (COVID-19) from Wuhan to Cities in China. medRxiv. 2020:2020.01.28.20019299.
74. Leung C. Estimating the distribution of the incubation period of 2019 novel coronavirus (COVID-19) infection between travelers to Hubei, China and non-travelers. medRxiv. 2020:2020.02.13.20022822.
75. Coronavirus disease 2019 (COVID-19) Situation Report, 0219. WHO. 2020.
76. Sun K, Chen J, Viboud C. Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study. The Lancet Digital Health. 2020;2(4):e201-e8.
77. Ding Y, Luo S, Zheng X, Ling P, Yue T, Liu Z, et al. Association of Population Migration and Coronavirus Disease 2019 Epidemic Control. medRxiv. 2020:2020.02.18.20024661.
78. Yang Y, Lu Q, Liu M, Wang Y, Zhang A, Jalali N, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv. 2020:2020.02.10.20021675.
79. Wang M, Jiang A, Gong L, Luo L, Guo W, Li C, et al. Temperature significant change COVID-19 Transmission in 429 cities. medRxiv. 2020:2020.02.22.20025791.
80. Chong YC. A Novel Method for the Estimation of a Dynamic Effective Reproduction Number (Dynamic-R) in the CoViD-19 Outbreak. medRxiv. 2020:2020.02.22.20023267.
81. Guan W-j, Liang W-h, Zhao Y, Liang H-r, Chen Z-s, Li Y-m, et al. Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis. medRxiv. 2020:2020.02.25.20027664.
82. Yang Z, Zeng Z, Wang K, Wong S, Liang W, Zanin M, et al. Modified SEIR and AI prediction of the epidemics trend of COVID-19 in China under public health interventions. Journal of Thoracic Disease. 2020;12(2):165-74.
83. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. The New England Journal of Medicine. 2020.
84. Li R, Lu W, Yang X, Feng P, Muqimova O, Chen X, et al. Prediction of the Epidemic of COVID-19 Based on Quarantined Surveillance in China. medRxiv. 2020:2020.02.27.20027169.
85. Han H. Estimate the incubation period of coronavirus 2019 (COVID-19). medRxiv. 2020:2020.02.24.20027474.
86. Yang K, Wang L, Li F, Chen D, Li X, Qiu C, et al. Analysis of epidemiological characteristics of coronavirus 2019 infection and preventive measures in Shenzhen China: a heavy population city. medRxiv. 2020:2020.02.28.20028555.
87. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts. medRxiv. 2020:2020.03.03.20028423.
88. Tindale L, Coombe M, Stockdale JE, Garlock E, Lau WYV, Saraswat M, et al. Transmission interval estimates suggest pre-symptomatic spread of COVID-19. medRxiv. 2020:2020.03.03.20029983.
89. Ping K. Epidemiologic Characteristics of COVID-19 in Guizhou, China. medRxiv. 2020:2020.03.01.20028944.
90. Kraemer MUG, Yang C-H, Gutierrez B, Wu C-H, Klein B, Pigott DM, et al. The effect of human mobility and control measures on the COVID-19 epidemic in China. medRxiv. 2020:2020.03.02.20026708.
91. Su L, Hong N, Zhou X, He J, Ma Y, Jiang H, et al. Evaluation of the secondary transmission pattern and epidemic prediction of COVID-19 in the four metropolitan areas of China. medRxiv. 2020:2020.03.06.20032177.
92. Jing Q, You C, Lin Q, Hu T, Yu S, Zhou X-H. Estimation of incubation period distribution of COVID-19 using disease onset forward time: a novel cross-sectional and forward follow-up study. medRxiv. 2020:2020.03.06.20032417.
93. Dorigatti I, Okell L, Cori A, Imai N, Baguelin M, Bhatia S, et al. Report 4: severity of 2019-novel coronavirus (nCoV). Imperial College London, London. 2020.
94. Shen M, Peng Z, Guo Y, Xiao Y, Zhang L. Lockdown may partially halt the spread of 2019 novel coronavirus in Hubei province, China. medRxiv. 2020:2020.02.11.20022236.
95. Zhang R, Liu H, Li F, Zhang B, Liu Q, Li X, et al. Transmission and epidemiological characteristics of Novel Coronavirus (2019-nCoV)-Infected Pneumonia(NCIP):preliminary evidence obtained in comparison with 2003-SARS. medRxiv. 2020.
96. Wilson N, Kvalsvig A, Telfar Barnard L, Baker M. Estimating the Case Fatality Risk of COVID-19 using Cases from Outside China. medRxiv. 2020:2020.02.15.20023499.
97. Diao Y, Liu X, Wang T, Zeng X, Dong C, Zhou C, et al. Estimating the cure rate and case fatality rate of the ongoing epidemic COVID-19. medRxiv. 2020:2020.02.18.20024513.
98. Mizumoto K, Chowell G. Estimating the risk of 2019 Novel Coronavirus death during the course of the outbreak in China, 2020. medRxiv. 2020:2020.02.19.20025163.
99. Sun P, Qie S, Liu Z, Ren J, Jianing Xi J. Clinical characteristics of 50466 patients with 2019-nCoV infection. medRxiv. 2020:2020.02.18.20024539.
100. Ying S, Li F, Geng X, Li Z, Du X, Chen H, et al. Spread and control of COVID-19 in China and their associations with population movement, public health emergency measures, and medical resources. medRxiv. 2020:2020.02.24.20027623.
101. Qi R, Ye C, Qin X-r, Yu X-J. Case fatality rate of novel coronavirus disease 2019 in China. medRxiv. 2020:2020.02.26.20028076.
102. Riou J, Hauser A, Counotte M, Althaus C. Adjusted age-specific case fatality ratio during the COVID-19 epidemic in Hubei, China, January and February 2020; 2020.
103. Li H, Wang S, Zhong F, Bao W, Li Y, Liu L, et al. Age-dependent risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China. medRxiv. 2020.
104. Deng X, Yang J, Wang W, Wang X, Zhou J, Chen Z, et al. Case fatality risk of novel coronavirus diseases 2019 in China. medRxiv. 2020:2020.03.04.20031005.
105. Russell TW, Hellewell J, Jarvis CI, van-Zandvoort K, Abbott S, Ratnayake R, et al. Estimating the infection and case fatality ratio for COVID-19 using age-adjusted data from the outbreak on the Diamond Princess cruise ship. medRxiv. 2020:2020.03.05.20031773.
106. Baud D, Qi X, Nielsensaines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infectious Diseases. 2020.